国内降糖药药物经济学研究的系统评估  

Pharmacoeconomic Study of Domestic Anti-diabetic Drug:Systematic Review

作　　者：孙晓[1] 郭利平[1] 商洪才[1] 任明[1] 霍达[1] 

机构地区：[1]天津中医药大学,七年制2007级天津300193

出　　处：《中国药房》2014年第18期1633-1637,共5页China Pharmacy

基　　金：国家重点基础研究发展计划(973计划)课题(No.2012CB518401);国家重点基础研究发展计划(973计划)课题(No.2009CB523003);教育部创新团队发展计划“中医药防治心血管疾病研究”课题(No.IRT1276)

摘　　要：目的:了解国内文献关于降糖药药物经济学研究情况,寻求成本效果较好的用药方案,探讨目前国内降糖药成本效果研究存在的不足。方法:计算机检索中国生物医学文献数据库(SinoMed)、中国学术期刊全文数据库(CNKI)、万方数据库、维普中文科技期刊数据库(VIP),并手工检索相关杂志,纳入从2003年至2013年国内研究降糖药药物经济学的随机临床干预研究文献,并对其进行分析。结果:最终纳入文献22篇,单纯研究西药降糖药的有21篇,涉及中药的有1篇。研究均是实际临床试验,比较不同降糖药的成本效果。研究的主要成本指标是直接药物成本,效果是血糖的改善情况,研究人群均为无并发症的2型糖尿病患者。研究的周期最长48周,最短4周,平均16周,仅有1篇进行随访。11篇文献考虑了不良事件的发生。结论:目前国内降糖药的药物经济学研究主要存在:方法不统一、成本计算和效果方法衡量标准不一等问题,导致已有文献无法进行综合分析,不能得出最佳成本效果的药物。今后的研究需要探寻相应的标准和方法,使各研究具有可比性。OBJECTIVE： To investigate the situation of pharmacokinetic study of anti-diabetic drug in domestic literatures and seek the medication plan with good cost-effectiveness, and to discuss the deficiency of domestic cost-effectiveness study of anti- diabetic drugs. METHODS： Retrieved from SinoMed, CNKI, Wanfang database and VIP by computer and manual retrieval of related magazines, domestic literatures about randomized clinical intervention for pharmacokinetics of anti-diabetic drugs were collected and analyzed from 2003 to 2013. RESULTS： A total of 22 literatures were included, involving 21 literatures of western medicines and I literature of TCM. All studies were clinical trials, and cost-effectiveness 0f different anti-diabetics were compared. In study, the main costs were direct drug costs, the effects were improvement of blood sugar, and the study populations were type 2 diabetes patients without complications. The longest cycle of study lasted for 48 weeks, the shortest was 4 weeks, and the average was 16 weeks. Only one literature referred to follow-up visiting, and 11 literatures referred to adverse events. CONCLUSIONS： Pharmacoeconomic study of domestic anti-diabetic drugs mainly have questions, such as non-unifurm methods; due to differences on the measures of the cost calculations, effects and methods, it is unable to analyze existed literatures and obtain drugs with best cost-effectiveness. The future study needs to seek for the corresponding standards and methods in order to make all studies have comparability.

关 键 词：降糖药 药物经济学 系统评估 

分 类 号：R977.15[医药卫生—药品] R956[医药卫生—药学]